Hemophilia is a rare genetic disorder whose treatment depends directly on advanced blood-clotting therapies. Producing these medicines requires sophisticated technology, specialized infrastructure, and advanced biotechnology expertise. Only a limited number of countries have mastered their production. According to available information, Iran is now among the few countries capable of manufacturing both strategic medicines, a position that is significant in terms of technological advancement, pharmaceutical security, and reduced reliance on imports

One of these medicines is Factor VIII, the primary treatment for patients with hemophilia A. Administered by injection to replace the missing clotting factor, it plays a vital role in preventing recurrent bleeding episodes and preserving patients' quality of life. The second is activated Factor VII (Factor VIIa), which is used to control severe bleeding, particularly in patients who have developed inhibitors against Factor VIII. It is considered one of the most critical lifesaving therapies for these patients.

According to available data, Iran, alongside Denmark, France, and Russia, is among the few countries that produce both Factor VIII and activated Factor VII (Factor VIIa). This demonstrates that Iran's pharmaceutical and biotechnology industries have mastered one of the world's most complex recombinant drug manufacturing technologies.

The number of countries producing Factor VIII is larger. Iran, China, Denmark, France, Russia, the US, Germany, Switzerland, South Korea, and Japan are among its manufacturers. In contrast, production of activated Factor VII (Factor VIIa) is far more limited, with only Iran, Denmark, France, and Russia identified as manufacturers.

Available information also indicates that while China manufactures Factor VIII, its Factor VIIa remains in the clinical trial stage and has not yet entered commercial production. The US, despite producing Factor VIII, serves only as a distributor of Factor VIIa and is not identified as a manufacturer. Likewise, Germany, Switzerland, South Korea, and Japan produce Factor VIII but do not manufacture Factor VIIa.

Iran's achievement in simultaneously producing these two strategic medicines represents more than an industrial success; it is also a major advance in health security. Domestic production improves patients' access to treatment, reduces dependence on imports, lowers foreign currency expenditures, and makes the healthcare system more resilient to disruptions in global pharmaceutical supply chains and international restrictions. The achievement also creates opportunities to expand exports of biopharmaceutical products and strengthen the position of Iran's pharmaceutical industry in regional and international markets.